Machine learning and artificial intelligence are all the rage today in venture capital circles. We’ve seen spectacular exits in the past few years, from Google absorbing Deepmind in 2014 for $500 million, to Twitter buying TellApart in 2015 for $533 million, and Intel swallowing Nervana in 2016 for $400 million. But these were all IT plays.
What happens when machine learning meets biology? Berkeley-based Lygos is engineering and designing microbes that convert low-cost sugar into high-value, specialty chemicals. At the core, they’re developing and exploiting a number of tools, both software and hardware, and applying them to biology.
Author: Matt Asay